Your Patient Needs Airsupra — Now What?

You've prescribed Airsupra (albuterol 90 mcg/budesonide 80 mcg) because it's the right choice for your patient's asthma management. The clinical rationale is sound — a rescue inhaler with built-in anti-inflammatory action addresses a well-documented gap in asthma care. But your patient calls back a day later: their pharmacy doesn't have it, or their insurance rejected it, or the copay is more than they can afford.

This is a common scenario in 2026. Airsupra is clinically valuable but operationally challenging to access. This guide provides concrete steps your practice can take to bridge that gap.

Current Availability: What Your Patients Are Running Into

As of March 2026, Airsupra is not in a formal drug shortage. AstraZeneca's supply chain is intact. The access problem is downstream:

• Many retail pharmacies don't stock it — the $479-$737 acquisition cost and limited demand make it a risky inventory item
• Chain pharmacies are the least likely to carry it — centralized inventory systems deprioritize newer brand-only products
• Prior authorization creates delays — many plans require PA or step therapy, and patients may abandon the prescription during the wait
• Patient cost-sharing is unpredictable — copays range from $0 to $100+ depending on the plan and tier placement

The result: patients hear "we don't carry that" and assume the problem is unsolvable. Your practice can change that narrative.

Why Patients Can't Find It (And Why It's Not Getting Better Fast)

Understanding the root causes helps set realistic expectations with patients:

1. Brand-only status: No generic exists, and none is expected in 2026. AstraZeneca is the sole manufacturer.
2. Novel drug class: As the first SABA/ICS rescue inhaler, pharmacy purchasing teams may not have established ordering protocols for it.
3. Economic incentive gap: Pharmacies earn thin margins on expensive brand drugs. Without steady demand, the financial case for stocking Airsupra is weak.
4. Formulary fragmentation: While ~80% of commercial plans cover it, the remaining 20% — plus the large Medicare and Medicaid populations — create a patchwork of coverage that suppresses overall demand.

What Your Practice Can Do: 5 Steps

Step 1: Use Medfinder to Identify Pharmacies with Stock

Medfinder for providers allows your staff to check real-time pharmacy availability for Airsupra before the patient even leaves the office. Instead of sending a patient out to hunt, you can direct them to a specific pharmacy that has it.

Consider integrating this check into your workflow: when prescribing Airsupra, have your MA or nurse check Medfinder and include the pharmacy name and phone number in the patient's discharge instructions.

Step 2: Send Prescriptions to Pharmacies That Stock It

Once you identify pharmacies that carry Airsupra (via Medfinder or direct outreach), add them to your e-prescribing favorites. Building relationships with 2-3 pharmacies that reliably stock Airsupra means smoother fills for all your patients on the medication.

Independent and specialty pharmacies tend to be more receptive than large chains. Respiratory-focused specialty pharmacies are your best bet for consistent availability.

Step 3: Proactively Handle Prior Authorization

If you know a patient's plan requires PA, initiate the process at the time of prescribing rather than waiting for a pharmacy rejection. Key documentation to include:

• Confirmed asthma diagnosis with severity classification
• History of rescue inhaler use frequency
• Clinical rationale for SABA/ICS combination (e.g., frequent rescue use, history of exacerbations, poor adherence to daily controller therapy)
• Previous trials of alternative therapies if step therapy is required

AstraZeneca provides PA support resources for providers — their healthcare professional portal includes template language and coverage lookup tools.

Step 4: Connect Patients with Savings Programs Before They Hit the Counter

Sticker shock at the pharmacy is a leading cause of prescription abandonment. Brief your patients on cost before they leave your office:

• SUPRA Savings Card: Commercially insured patients may pay $0 (up to $130 savings/inhaler) — airsupra.com/savings-card or 1-866-480-0030
• AstraZeneca Direct: ~$249/inhaler with home delivery — azpatientdirect.com
• AZ&Me Patient Assistance: Free/reduced-cost for qualifying uninsured patients — azandmeapp.com

Note: The savings card is not valid for government-insured patients (Medicare, Medicaid, VA, TRICARE). Direct these patients to AZ&Me or consider AstraZeneca Direct.

Step 5: Provide a Backup Plan

Always discuss what the patient should do if they can't fill the Airsupra prescription. This might include:

• A standard albuterol inhaler as a bridge (prescribe simultaneously as a safety net)
• Instructions to call your office if they can't fill within 48 hours
• A follow-up plan to reassess if they end up on an alternative long-term

Alternative Prescribing Strategies

When Airsupra isn't accessible, the following alternatives provide varying degrees of the same therapeutic concept:

• Albuterol + separate daily ICS: The traditional approach. Works well for adherent patients but doesn't provide anti-inflammatory action at the point of rescue.
• Symbicort or Breyna in MART approach: Budesonide/formoterol used as both maintenance and reliever therapy. Closest to Airsupra's dual-action concept but uses a LABA instead of SABA for the bronchodilator component.
• Levalbuterol (Xopenex): For patients who experience significant side effects with standard albuterol. Doesn't address the inflammation gap but may be better tolerated.

For a patient-facing comparison, see our article on alternatives to Airsupra.

Workflow Tips for Your Practice

A few small workflow adjustments can significantly reduce friction:

• Create an Airsupra prescribing checklist — include Medfinder stock check, savings card enrollment, and PA initiation as standard steps
• Keep savings card information in your EMR — add the SUPRA Savings Card phone number (1-866-480-0030) and website as a quick reference
• Designate a staff member for access issues — having one person who knows the Airsupra access landscape can save the whole practice time
• Follow up at 1 week — a quick check-in to confirm the patient filled and started using Airsupra catches access problems before they become clinical problems

Final Thoughts

Prescribing Airsupra in 2026 requires more than writing the prescription — it requires an access strategy. The clinical benefit is clear, but getting the medication into the patient's hands takes proactive effort from the entire care team.

Use Medfinder for providers to streamline pharmacy identification, connect patients with savings programs upfront, and always have a backup plan. The landscape is improving, but it's not there yet.

For more on the Airsupra supply landscape, see our provider shortage briefing or check out the provider's guide to helping patients save on Airsupra.